Browsing Tag
gene therapy
71 posts
Genenta Science partners with Anemocyte to unlock scalable LVV plasmid DNA supply for global cell and gene therapy developers
Find out how Genenta Science and Anemocyte are scaling off-the-shelf LVV plasmid DNA to revolutionize global gene and cell therapy manufacturing.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Oxford Biomedica (LSE: OXB) expands US manufacturing base with Durham viral vector facility buy
Find out how Oxford Biomedica’s new US viral vector facility strengthens its CDMO leadership and growth trajectory.
Base editing 101: Is precision gene editing safer than CRISPR‑Cas9 for therapeutic use?
Is base editing safer than CRISPR? See how Beam, Verve, and Prime are using non-cutting gene editing to raise the bar for precision and clinical safety.
Base editing vs CRISPR: Why Beam Therapeutics’ sickle cell therapy may quietly become a blockbuster
Weeks after Beam’s BEAM-101 earned RMAT status, here’s why base editing may still reshape sickle cell therapy—and what investors should watch next.
Sarepta Therapeutics awards 25 Route 79 scholarships in 2025–2026, but what makes this Duchenne program unique?
Sarepta Therapeutics awarded 25 Route 79 scholarships for 2025–2026 to support students impacted by Duchenne. See how this initiative strengthens community ties.
Why Rocket Pharmaceuticals shareholders are filing suit over adverse event risks in RP-A501
A class action lawsuit claims Rocket Pharmaceuticals misled investors about the safety and effectiveness of its gene therapy. Find out what’s at stake.
Rocket Pharmaceuticals receives FDA clearance to begin human trials for RP-A701 in treating BAG3-associated dilated cardiomyopathy
Rocket Pharmaceuticals earns FDA IND clearance for RP-A701, advancing gene therapy for rare BAG3-associated dilated cardiomyopathy. Trial begins in U.S.
Klotho Neurosciences begins manufacturing KLTO-202 gene therapy to advance clinical trials in ALS
Klotho Neurosciences begins KLTO-202 manufacturing to prepare for ALS clinical trials, with a gene therapy targeting neuroprotection in spinal neurons.
GenSight Biologics completes LUMEVOQ tech transfer to Catalent to enable global clinical expansion
GenSight Biologics advances gene therapy LUMEVOQ® through strategic manufacturing transfer to Catalent, bolstering regulatory readiness and clinical scale-up.